EYLEA: Solution for injection (40mg)

Detailed Information

ON THIS PAGE:
What is this Medicine?
In-Depth Information
Learn More
Patient Experiences

Also see:

Get answers to Frequently Asked Questions (FAQs)
Find other class related drugs
Find additional patient usage statistics

Visit Drug Summary Page

Check Drug Interactions

What is this Medicine?

AFLIBERCEPT (a FLIB er sept) is an injectable medicine for the eye. It is used to treat wet age-related macular degeneration (AMD) and macular edema, including diabetic macular edema. This drug is also used to treat diabetic retinopathy in patients with diabetic macular edema. This medicine helps to slow the disease and may help to maintain vision. It is not a cure.

In-Depth Information

EYLEA 2mg/0.05ml Solution for Injection

NDC: 617550005

Prescription Required
Not a Controlled Drug
(CSA Schedule)
FDA Approved

FDA approved for the following conditions:
Macular Edema Following Retinal Vein Occlusion, Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema

Storage Information
Refrigerate (between 36 and 46 degrees F)
Store in original package until time of use
Protect from light
Discard product if it contains particulate matter, is cloudy, or discolored
Do not freeze

EYLEA 2mg/0.05ml Solution for Injection

Ingredients

Close All Sections

Reported Side Effects for EYLEA 2mg/0.05ml Solution for Injection

Endophthalmitis Incidence: <1.0%* Severity: SEVERE
Onset: DELAYED

Blood Clot Incidence: <3.3%* Severity: SEVERE
Onset: DELAYED

Corneal Edema Incidence: <1.0%* Severity: MODERATE
Onset: EARLY

Cataracts Incidence: <7.0%* Severity: MODERATE
Onset: DELAYED

Heart Attack Incidence: <3.3%* Severity: SEVERE
Onset: DELAYED

Retinal Detachment Incidence: <1.0%* Severity: SEVERE
Onset: DELAYED

Brain Attack Incidence: <3.3%* Severity: SEVERE
Onset: EARLY

Swollen Eyelids Incidence: <1.0%* Severity: MILD
Onset: EARLY

Injection Site Reaction Incidence: 1.0-3.0%* Severity: MILD
Onset: RAPID

Blurred Vision Incidence: 1.0-2.0%* Severity: MODERATE
Onset: EARLY

Secretion Of Tears Incidence: 3.0%* Severity: MILD
Onset: EARLY

Foreign Body Sensation Incidence: 3.0%* Severity: MILD
Onset: RAPID

Corneal Erosion Incidence: 4.0-5.0%* Severity: SEVERE
Onset: DELAYED

Red Eyes Incidence: 4.0-5.0%* Severity: MODERATE
Onset: EARLY

High Eye Blood Pressure Incidence: 5.0-8.0%* Severity: SEVERE
Onset: RAPID

Eye Pain Incidence: 9.0-13.0%* Severity: MILD
Onset: EARLY

Bleeding Within The Eye Incidence: 12.0-25.0%* Severity: SEVERE
Onset: DELAYED

*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.

Pregnancy & Lactation Information

FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

THIRD Trimester

Learning More About

Visit the Drug Summary page where you can: